Crossref

1. Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C

- Mahdiyar Pouresmaeeli

- Seyed Moayed Alavian

- Maryam Keshvari

- Shima Salimi

- Leila Mehrnoush

2. Vitamin D in Standard HCV Regimen (PEG-Interferon Plus Ribavirin), Its Effect on the Early Virologic Response Rate: A Clinical Trial

- Hasan Vosoghinia

- Abbas Esmaeilzadeh

- Azita Ganji

- Seyed Mousal-Reza Hosseini

- Saeid Amel Jamehdar

- Maryam Salehi

- Ali Bahari

- Omid Ghanaei

- Maryam Sahebari

- Farnood Rajabzadeh

- Kamran Ghaffarzadehgan

- Ladan Goshayeshi

3. Some Considerations About Cardiac Toxicity of Combination Therapy for Chronic Hepatitis C

- Reza Karbasi-Afshar

- Amin Saburi

4. lasma Zinc Level in Hepatitis C Patients With or Without Beta Thalassemia Major; Is There Any Difference?

- Mohammad Abbasinazari

- Bita Behnava

- Yunes Panahi

- Azita Hajhossein Talasaz

- Shima Salimi

- Maryam Keshvari

- Leila Mehrnoush

- Pegah karim

- Mohammad Gholami Fesharaki

- Mansour Asgharinia

- Seyed Moayed Alavian

5. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline

- Seyed Moayed Alavian

- Behzad Hajarizadeh

- Kamran Bagheri Lankarani

- Heidar Sharafi

- Nasser Ebrahimi Daryani

- Shahin Merat

- Minoo Mohraz

- Masoud Mardani

- Mohamad Reza Fattahi

- Hossein Poustchi

- Mehri Nikbin

- Mahmood Nabavi

- Peyman Adibi

- Masood Ziaee

- Bita Behnava

- Mohammad Saeid Rezaee-Zavareh

- Massimo Colombo

- Hatef Massoumi

- Abdul Rahman Bizri

- Bijan Eghtesad

- Majid Amiri

- Ali Namvar

- Khashayar Hesamizadeh

- Reza Malekzadeh

6. Predicting the Outcomes of Combination Therapy in Patients With Chronic Hepatitis C Using Artificial Neural Network

- Forough Sargolzaee Aval

- Nazanin Behnaz

- Mohamad Reza Raoufy

- Seyed Moayed Alavian

7. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients

- Arghavan Haj-sheykholeslami

8. The Evaluation of Interferon Lambda 4 rs368234815 as a Predictor Factor in Treated Patients with Chronic Hepatitis C Genotype 1a Infection

- Shahram Jalilian

- Seyed Mahmoud Latifi

- Manoochehr Makvandi

- Ali Teimoori

- Azarakhsh Azaran

- Mehdi Parsanahad

- Gholamabas Kayedani

9. Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients

- Farah Bokharaei-Salim

- Hossein Keyvani

- Mostafa Salehi-Vaziri

- Farzin Sadeghi

- Seyed Hamidreza Monavari

- Leila Mehrnoush

- Seyed Moayed Alavian

10. Hepatitis C Therapy – Related Haematological Side Effects are Associated with Treatment Outcome / Hematološka Neželjena Dejstva Terapije Hepatitisa C Su Povezana Sa Ishodom Lecenja

- Vuk R. Vukovic

- Dejan Baskic

- Zeljko Mijailovic

- Predrag Djurdjevic

11. Hepatitis C and Why the Treatment is Needed Now? The Summary Report From the Cross-Border Symposium of the 5th Tehran Hepatitis Congress May 2013

- Nasser Ebrahimi Daryani

- Seyed Moayed Alavian

- Mohammad Hossein Somi

- Mohammad Torabi-Nami

12. Psychiatric side effects of pegylated interferon‑α and ribavirin therapy in Iranian patients with chronic hepatitis C: A meta‑analysis

- Lotfollah Davoodi

- Babak Masoum

- Mahmood Moosazadeh

- Hamed Jafarpour

- Mohammad Haghshenas

- Tahoora Mousavi

13. Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNα-2a and ribavirin in Iranian patients with chronic hepatitis C

- Farzin Sadeghi

- Farah Bokharaei-Salim

- Mostafa Salehi-Vaziri

- Seyed Hamidreza Monavari

- Seyed Moayed Alavian

- Shima Salimi

- Rouhollah Vahabpour

- Hossein Keyvani

14. Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population

- Amitis Ramezani

- Kazem Baesi

- Mohammad Banifazl

- Minoo Mohraz

- Farzin Khorvash

- Majid Yaran

- Payam Tabarsi

- Amir hosein Dalirrooyfard

- Fatemeh Motevalli

- Anahita Bavand

- Arezoo Aghakhani

15. Adherence to Chronic Hepatitis C Treatment Regimen: First Report From a Referral Center in Iran

- Saeedeh Ravi

- Mohsen Nasiri Toosi

- Iman Karimzadeh

- Mehdi Ahadi-Barzoki

- Hossein Khalili

16. Epidemiology of hepatitis C virus in Iran

- Reza Taherkhani

17. IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C

- Parvaneh Sedighimehr

- Shiva Irani

- Fatemeh Sakhaee

- Farzam Vaziri

- Mohammadreza Aghasadeghi

- Seyed Mehdi Sadat

- Fatemeh Rahimi Jamnani

- Abolfazl Fateh

- Seyed Davar Siadat

18. Determination of Whether Vitiligo is a Contraindication to Interferon Therapy in Chronic Hepatitis C

- Seyed Moayed Alavian

19. Prevalence of Hepatitis C Virus Genotypes Among Patients in Countries of the Eastern Mediterranean Regional Office of WHO (EMRO): A Systematic Review and Meta-Analysis

- Farzin Sadeghi

- Mostafa Salehi-Vaziri

- Amir Almasi-Hashiani

- Mohammad Gholami-Fesharaki

- Reza Pakzad

- Seyed Moayed Alavian

20. Risk Factors for Migraine Attacks in Patients Undergoing Treatment for Hepatitis C

- Razie Salesi

- Asieh Salesi

- Faraidoon Haghdoost

- Seyed Moayed Alavian